SWITZERLAND - BioMedPartners reaches final close on CHF 106m

The fund will invest in biotechnology, medical technology and pharmaceutical companies in Switzerland, Germany, and neighboring European countries. The investor plans to build a portfolio of around 15 firms.

In addition, the firm has hired Dr Karl Deres as a new venture partner in the Munich office who will join the management. Dr Deres has worked for 15 years for Bayer Schering Pharma und Invervet Schering Plough. In 2007 he founded DPC Pharma Consulting.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Venture
• Healthcare
• DACH